The 2017 Annual Meeting of the American Urological Association, held at the Boston Convention and Exhibition Center in May, saw excellent turnout. Some of the educational sessions were highly relevant to Sekisui Diagnostics.
This was the 112th annual meeting of the AUA – a leading industry organization for urologists and global urologic health care professionals and the “largest gathering of urologists in the world.” It is an excellent venue for learning the current developments in research, as well getting a first-hand look at some of the latest technology used in urologic medicine.
This year’s event was truly global in nature, with a large international presence representing (among other places) Liberia, the UK, New Zealand, Uruguay, Egypt, South Africa, Spain and elsewhere. Without fail, Point-of-Care testing was top-of-mind – especially among doctors and medical practitioners.
Hot Topics at AUA
In addition to cost, EMR interfacing was one of the most common questions our team fielded at the show. In fact, we’ve been fielding this question more and more frequently in the past few years as Electronic Medical Records have become standard industry practice. (Sekisui Diagnostics Fastpack IP system has the ability to download test data and interface with practice EMRs through a data port).
Of particular interest to attendees was Sekisui’s PSA test (read our earlier post on the Prostate-Specific Antigen, or PSA, Test). As mentioned above, there were a number of sessions relevant to the topic of prostate cancer.
Among them was Dr. Isaac Yi Kim (Research does not support changes to active surveillance criteria based on race, lecturer says), who referenced the disparities between African American men and Caucasians in the incidence of prostate cancer. At Monday’s Plenary session, Dr. Kim – Acting Chief of the Division of Urology at the Rutgers Robert Wood Johnson Medical School and Chief of the Section of Urologic Oncology at Rutgers Cancer Institute of New Jersey – stated “there are not enough data at this time to support modifying active surveillance criteria based on race.”
In another roundtable session moderated by Dr. Ian Thompson, Jr., experts discussed some of the challenges presented by prostate cancer, including “prostate specific antigen (PSA) recurrence in patients who have undergone radical prostatectomy.”
A number of other sessions – including poster sessions – also focused on the topic of prostate cancer – from screening & detection through to treatment & follow-up.
Other products of interest at the AUA show included our bacterial vaginosis (BV) tests, as well as other rapid tests & diagnostics from our extensive women’s health product line.
All in all, it was wonderful to catch up with our customers. Especially nice: receiving the feedback that some Sekisui Diagnostics products & systems with nearly a decade-and-a-half of hard clinical use are still going strong and delivering value for our customers!